Andreas Norlin
Chief Tech/Sci/R&D Officer bij ASCELIA PHARMA AB
Vermogen: 10 650 $ op 31-03-2024
Profiel
Andreas L.
Norlin is the founder of Xkout Bioscience AB.
He is currently the Director at ApoGlyx AB and the Chief Scientific Officer at Ascelia Pharma AB.
Dr. Norlin has a graduate and doctorate degree from the University of Lund.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
ASCELIA PHARMA AB
0.04% | 13-07-2023 | 12 364 ( 0.04% ) | 10 650 $ | 31-03-2024 |
Actieve functies van Andreas Norlin
| Bedrijven | Functie | Begin |
|---|---|---|
| ASCELIA PHARMA AB | Chief Tech/Sci/R&D Officer | 01-01-2020 |
ApoGlyx AB
 ApoGlyx AB BiotechnologyHealth Technology ApoGlyx AB engages in research and development of aquaporin inhibitors. It conducts sales of know-how, licenses, and chemical substance in biochemistry. The company was founded by Per Ola Kjellbom on April 22, 2008 and is headquartered in Lund, Sweden. | Director/Board Member | - |
Eerdere bekende functies van Andreas Norlin
| Bedrijven | Functie | Einde |
|---|---|---|
| Xkout Bioscience AB | Founder | - |
Opleiding van Andreas Norlin
| University of Lund | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| ASCELIA PHARMA AB | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
ApoGlyx AB
ApoGlyx AB BiotechnologyHealth Technology ApoGlyx AB engages in research and development of aquaporin inhibitors. It conducts sales of know-how, licenses, and chemical substance in biochemistry. The company was founded by Per Ola Kjellbom on April 22, 2008 and is headquartered in Lund, Sweden. | Health Technology |
| Xkout Bioscience AB |
